ATE373652T1 - Kristallformen von 2-(5-chlorthien-2-yl)-n-((3s)- 1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2 oxopyrrolidin-3-yl)ethensulfonamid - Google Patents

Kristallformen von 2-(5-chlorthien-2-yl)-n-((3s)- 1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2 oxopyrrolidin-3-yl)ethensulfonamid

Info

Publication number
ATE373652T1
ATE373652T1 AT03789150T AT03789150T ATE373652T1 AT E373652 T1 ATE373652 T1 AT E373652T1 AT 03789150 T AT03789150 T AT 03789150T AT 03789150 T AT03789150 T AT 03789150T AT E373652 T1 ATE373652 T1 AT E373652T1
Authority
AT
Austria
Prior art keywords
chlorthien
ethenesulfonamide
oxopyrrolidine
oxoethyl
morpholine
Prior art date
Application number
AT03789150T
Other languages
English (en)
Inventor
Orco Philip Dell
Henry Kelly
Gita Shah
Nigel Watson
Robert Young
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE373652T1 publication Critical patent/ATE373652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03789150T 2002-12-06 2003-12-04 Kristallformen von 2-(5-chlorthien-2-yl)-n-((3s)- 1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2 oxopyrrolidin-3-yl)ethensulfonamid ATE373652T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228533.6A GB0228533D0 (en) 2002-12-06 2002-12-06 Crystalline form

Publications (1)

Publication Number Publication Date
ATE373652T1 true ATE373652T1 (de) 2007-10-15

Family

ID=9949229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789150T ATE373652T1 (de) 2002-12-06 2003-12-04 Kristallformen von 2-(5-chlorthien-2-yl)-n-((3s)- 1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2 oxopyrrolidin-3-yl)ethensulfonamid

Country Status (28)

Country Link
US (1) US7645338B2 (de)
EP (1) EP1567519B1 (de)
JP (1) JP4660197B2 (de)
KR (1) KR20050085328A (de)
CN (1) CN100378098C (de)
AR (1) AR042304A1 (de)
AT (1) ATE373652T1 (de)
AU (1) AU2003293779B2 (de)
BR (1) BR0317067A (de)
CA (1) CA2508699A1 (de)
CY (1) CY1107011T1 (de)
DE (1) DE60316467T2 (de)
DK (1) DK1567519T3 (de)
ES (1) ES2290541T3 (de)
GB (1) GB0228533D0 (de)
HK (1) HK1083491A1 (de)
IS (1) IS7927A (de)
MA (1) MA27574A1 (de)
MX (1) MXPA05006032A (de)
MY (1) MY139916A (de)
NO (1) NO20053167L (de)
NZ (1) NZ540365A (de)
PL (1) PL377184A1 (de)
PT (1) PT1567519E (de)
RU (1) RU2339634C2 (de)
TW (1) TW200420560A (de)
WO (1) WO2004052878A2 (de)
ZA (1) ZA200504384B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268281A1 (en) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6602864B1 (en) * 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
AU2001255408A1 (en) * 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors
AU2001288228A1 (en) * 2000-07-27 2002-02-13 Zetetic Institute Multiple-source arrays for confocal and near-field microscopy
AU2001280979A1 (en) * 2000-08-02 2002-02-13 Captivads, Inc. Interactive advertising and multi-media system with a plurality of mobile platforms
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) * 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE60316467D1 (en) 2007-10-31
NO20053167L (no) 2005-06-28
DK1567519T3 (da) 2008-01-28
GB0228533D0 (en) 2003-01-15
AU2003293779B2 (en) 2008-01-31
ES2290541T3 (es) 2008-02-16
IS7927A (is) 2005-07-01
PL377184A1 (pl) 2006-01-23
MA27574A1 (fr) 2005-10-03
RU2339634C2 (ru) 2008-11-27
CN1745079A (zh) 2006-03-08
US20060124049A1 (en) 2006-06-15
AR042304A1 (es) 2005-06-15
NZ540365A (en) 2008-01-31
PT1567519E (pt) 2007-12-17
WO2004052878A2 (en) 2004-06-24
WO2004052878A3 (en) 2004-08-12
AU2003293779A1 (en) 2004-06-30
MY139916A (en) 2009-11-30
CN100378098C (zh) 2008-04-02
JP4660197B2 (ja) 2011-03-30
EP1567519A2 (de) 2005-08-31
BR0317067A (pt) 2005-10-25
ZA200504384B (en) 2006-03-29
HK1083491A1 (en) 2006-07-07
DE60316467T2 (de) 2008-06-12
CA2508699A1 (en) 2004-06-24
MXPA05006032A (es) 2005-08-18
RU2005121262A (ru) 2006-01-20
KR20050085328A (ko) 2005-08-29
TW200420560A (en) 2004-10-16
CY1107011T1 (el) 2012-09-26
US7645338B2 (en) 2010-01-12
EP1567519B1 (de) 2007-09-19
JP2006510648A (ja) 2006-03-30

Similar Documents

Publication Publication Date Title
ATE428428T1 (de) Kombination von azelastine und fluticasone
ATE443048T1 (de) 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
DE60313289D1 (de) Kontrollierte synthese von ziprasidon
DE602004020156D1 (de) Verwaltung von Rahmenbursts
DE60315568D1 (de) Bildschärfeverbesserung von numerischen Bildern
ATE510556T1 (de) Verwendung von erythropoietin
ATE477803T1 (de) Metabolit von quetiapine
DE60334261D1 (de) Internet basierte Verwaltung von Bildersammlungen
DE60315191D1 (de) Verwendung von multifunktionellen tensidenzur reinigung von kontaktlinsen
NO20041449L (no) Krystallinformer av valasyklovir-hydroklorid
ATE364610T1 (de) Kristalline polymorphe form von irinotecan- hyrochlorid
ATE343567T1 (de) Breitspektrum 2-(substituierte-amino)- benzothiazol-sulfonamide hiv protease inhibitoren
DE60232290D1 (de) Kontrollierte Auflösung von Wirkstoffen
ATE444290T1 (de) Oxazolderivate von tetracyclinen
DE60227828D1 (de) E von schmelzkleber
DE60141146D1 (de) Adressierung von multistabilen nematischen fluessigkristallvorrichtungen
ATE373652T1 (de) Kristallformen von 2-(5-chlorthien-2-yl)-n-((3s)- 1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2 oxopyrrolidin-3-yl)ethensulfonamid
NO20043114L (no) Bredspektrede heterocyklisk substituerte fenylinneholdende sulfonamid-HIV-proteaseinhibitorer
ATE556564T1 (de) Zuweisung von zeitschlitzen
DE60327426D1 (de) Markierung von substraten
DE60216525D1 (de) Reinigungsverfahren von aromaten
DE602004031534D1 (de) Stabiler polymorph von bifeprunoxmesilat
DE60320019D1 (de) Flüssigkristallpolymerzusammensetzung
DE60226570D1 (de) Verpackung von elektronischen Bauteilen
DK1440067T3 (da) N-formyl-derivater af paroxetin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1567519

Country of ref document: EP

REN Ceased due to non-payment of the annual fee